Biotech Startups

Remepy develops "Hybrid Drugs" that combine pharmaceuticals with targeted digital interventions to deliver personalized and adaptive therapies for patients. It operates in the digital health and biotech space, aiming to treat conditions through a combination of biology, behavior, and technology.

10 investors

Restore Vis is a life sciences company founded by a vitreoretinal surgeon and clinician scientist focused on addressing inflammation, aging, neurodegeneration and angiogenesis through translational research from drug discovery to clinical trials. The company develops treatments for ophthalmology and vision-related conditions.

10 investors

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases. The company uses proprietary platform technologies to create targeted and durable Treg cell therapies.

10 investors

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

10 investors

Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

10 investors

Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics. The company operates in the biotech/oncology drug development industry, with sites in Munich, Cambridge (MA), and Lausanne.

10 investors

4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases. The company uses its Therapeutic Vector Evolution platform to design customized vectors for targeted treatment delivery.

9 investors

Abalone Bio develops activating antibodies (agonists) targeting hard-to-drug receptors such as G-protein coupled receptors, using engineered cells to measure antibody pharmacological activity at high throughput combined with machine learning. Its initial focus is cell-specific antibody drugs for obesity and metabolic disease aimed at avoiding the GI side effects associated with GLP-1 therapies.

9 investors

Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch. It develops drug candidates like ABS-201 for conditions including androgenetic alopecia and applies reverse immunology for novel target discovery.

9 investors

Adaptyv Bio develops technologies for protein engineering that enable the design and testing of new proteins for applications in medicine, industrial enzymes, and functional materials. The company serves protein engineers and researchers developing therapeutic and industrial biological products.

9 investors

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.

9 investors

Aleph Farms develops cultivated meat, growing beef steaks from cow cells using tissue engineering technology, and produced the world's first cultivated thin-cut and ribeye steaks. The company received the world's first regulatory approval for cultivated beef and markets its products under the Aleph Cuts brand.

9 investors

Amgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.

9 investors

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.

9 investors

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments. The company focuses on oncology and cell therapy programs.

9 investors

Avro Life Science develops transdermal skin patches for delivering generic drugs. The company operates in the biotech and drug delivery space.

9 investors

Beacon Biosignals develops AI-powered EEG analytics technology to improve diagnosis and treatment of neurological, psychiatric, and sleep disorders. The company combines machine learning with neuroscience domain expertise to accelerate innovation for biopharma partners and clinical research organizations.

9 investors

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.

9 investors

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications. The company markets cells and disease models through its ioCells brand for use in biomedical research and therapeutic development.

9 investors

Blank Bio develops RNA foundation models for precision oncology, helping pharmaceutical companies identify the right patients for clinical trials and predict disease progression using bulk RNA-seq data. The company applies AI to patient selection and disease trajectory modeling to improve clinical trial outcomes.

9 investors

Cabinet provides a platform for retailers to build private-label OTC and Rx medicine programs, covering formulation, sustainable packaging, and supply chain execution, and connects manufacturers to demand. It offers medicines in multiple formats with capabilities like clean-label, third-party testing, and refillable plastic-free packaging.

9 investors

Cambrium designs novel molecules and materials by combining AI with bioscience disciplines such as molecular biology, protein engineering, and material science. It develops engineered proteins and materials for industrial and commercial applications.

9 investors

CarbonBridge develops a proprietary direct gas bioprocessing platform for bioreactor operations that eliminates solubility barriers without traditional equipment like spargers or agitators. The platform serves biotech and industrial biology companies seeking higher productivity and faster response times in bioprocessing.

9 investors

Carlsmed develops the aprevo personalized surgery platform for spine fusion procedures, producing patient-specific implants and technology used by spine surgeons. The company operates in the medical device industry with FDA-cleared lumbar and cervical fusion products.

9 investors